Compare NTLA & ALNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | ALNT |
|---|---|---|
| Founded | 2014 | 1962 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2016 | 1995 |
| Metric | NTLA | ALNT |
|---|---|---|
| Price | $12.40 | $118.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 5 |
| Target Price | $24.00 | ★ $118.00 |
| AVG Volume (30 Days) | ★ 4.0M | 186.4K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 0.13% |
| EPS Growth | 27.43 | ★ 67.09 |
| EPS | N/A | ★ 0.93 |
| Revenue | $67,671,000.00 | ★ $554,478,000.00 |
| Revenue This Year | N/A | $8.52 |
| Revenue Next Year | $143.36 | $9.07 |
| P/E Ratio | ★ N/A | $127.66 |
| Revenue Growth | ★ 16.92 | 4.62 |
| 52 Week Low | $7.95 | $42.42 |
| 52 Week High | $28.24 | $120.56 |
| Indicator | NTLA | ALNT |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 66.53 |
| Support Level | $11.49 | $81.89 |
| Resistance Level | $12.97 | $118.67 |
| Average True Range (ATR) | 0.71 | 5.00 |
| MACD | 0.06 | 1.29 |
| Stochastic Oscillator | 53.47 | 91.26 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Allient Inc, formerly Allied Motion Technologies Inc designs, manufactures, and sells precision and specialty controlled motion components and systems. The firm mainly caters to the Industrial, Vehicle, Aerospace & Defense, and Medical sectors. It mainly operates and sells across the United States, Canada, South America, Europe, and Asia. Its products and solutions include nano precision positioning systems, servo control systems, motion controllers, digital servo amplifiers and drives, brushless servo, torque, and coreless motors, brush motors, integrated motor drives, gear motors, gearing, incremental and absolute optical encoders, active (electronic) and passive (magnetic) filters for power quality and harmonic issues.